US2020048335A1PendingUtilityA1

Novel use of regulatory t cell-specific surface protein lrig-1

64
Assignee: GOOD T CELLS INCPriority: Jan 24, 2011Filed: Oct 2, 2019Published: Feb 13, 2020
Est. expiryJan 24, 2031(~4.5 yrs left)· nominal 20-yr term from priority
Inventors:Sang-Kyou Lee
A61P 35/00G01N 33/6872C12N 15/1138C12N 2310/14C07K 14/47C12Q 1/6876C12N 2310/11C07K 16/18G01N 33/5302G01N 33/5023C12Q 2600/136G01N 33/15G01N 33/9493C12N 2310/17C12Q 2600/158A61K 38/00C12Q 1/68G01N 33/6854C12Q 2600/178C12N 15/113A61K 35/17G01N 33/505
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.

Claims

exact text as granted — not AI-modified
1 . A method for treating cancer, comprising administering an effective amount of siRNA complementary to a nucleotide encoding Lrig1 protein expressed in regulatory T cells. 
     
     
         2 . The method of  claim 1 , wherein the siRNA is any one of siRNA as set forth in SEQ ID NO: 7, 8, 9, or 10. 
     
     
         3 . The method of  claim 1 , wherein the Lrig1 protein is set forth in SEQ ID NO: 11. 
     
     
         4 . The method of  claim 1 , wherein a cell membrane surface protein of Lrig1 protein is set forth in SEQ ID NO: 13.

Join the waitlist — get patent alerts

Track US2020048335A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.